The Acentus transaction follows Henry Schein’s acquisition of Prism Medical Products, LLC in 2021 and Shield Healthcare and ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Henry Schein HSIC is well positioned to gain from its extensive global foothold and diverse channel mix. Yet, global economic ...

Shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” ...

This was the stock's second consecutive day of losses.

Fintel reports that on January 6, 2025, B of A Securities upgraded their outlook for Henry Schein (NasdaqGS:HSIC) from ...

Henry Schein is launching a relief fund to provide essential medical supplies to support victims of the Los Angeles wildfires. The company is committing up to $300,000, including $150,000 in cash and ...

NAW said Henry Schein’s CEO won the award for his leadership, service and engagement with the association and distribution ...

The projected fair value for Henry Schein is US$67.04 based on 2 Stage Free Cash Flow to Equity With US$70.70 share price, Henry Schein appears to be trading close to its estimated fair value ...

Henry Schein has opened the Henry Schein Cares Foundation 2025 Relief Fund to support those impacted by the Los Angeles area wildfires.

Henry Schein, Inc.’s HSIC joint venture, Henry Schein One, is driving strong growth in its core products and introducing new solutions. The company’s robust acquisition strategy helps it to ...

Henry Schein (Nasdaq: HSIC) announced today that it completed the acquisition of substantially all the assets of Acentus.